Trials / Unknown
UnknownNCT06042764
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of Novel Coronavirus Broad-spectrum Neutralizing Antibody SA55 Injection in the Treatment of Mild/Moderate COVID-19 Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Sinovac Life Sciences Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SA55 Injection | Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II) |
Timeline
- Start date
- 2023-08-31
- Primary completion
- 2024-03-01
- Completion
- 2024-08-30
- First posted
- 2023-09-21
- Last updated
- 2023-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06042764. Inclusion in this directory is not an endorsement.